GSK Zoster2-Observer blind study to evaluate efficacy, safety, and immunogenictiy of GSK Biologicals Herpes Zoster vaccine

Investigator: Charalambos (Babis) Andreadis, MD
Sponsor: GlaxoSmithKline

Location(s): United States


The purpose of this study is to evaluate the efficacy of GSK Biologicals' vaccine GSK1437173A in the prevention of Herpes zoster (HZ) in autologous haematopoietic cell transplant recipients 18 years of age and older. To this end, the study will evaluate vaccine efficacy (VE) of the GSK1437173A vaccine, administered on a 2-dose schedule, compared to placebo in reducing the risk of developing HZ in this population.